261 related articles for article (PubMed ID: 28350808)
41. Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains.
O'Nuallain B; Allen A; Kennel SJ; Weiss DT; Solomon A; Wall JS
Biochemistry; 2007 Feb; 46(5):1240-7. PubMed ID: 17260953
[TBL] [Abstract][Full Text] [Related]
42. Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains.
Klimtchuk ES; Peterle D; Bullitt E; Connors LH; Engen JR; Gursky O
Amyloid; 2023 Dec; 30(4):364-378. PubMed ID: 37216473
[TBL] [Abstract][Full Text] [Related]
43. Development and characterization of a prototypic pan-amyloid clearing agent - a novel murine peptide-immunoglobulin fusion.
Foster JS; Balachandran M; Hancock TJ; Martin EB; Macy S; Wooliver C; Richey T; Stuckey A; Williams AD; Jackson JW; Kennel SJ; Wall JS
Front Immunol; 2023; 14():1275372. PubMed ID: 37854603
[TBL] [Abstract][Full Text] [Related]
44. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain.
Kobayashi Y; Tsutsumi H; Abe T; Ikeda K; Tashiro Y; Unzai S; Kamikubo H; Kataoka M; Hiroaki H; Hamada D
Biochemistry; 2014 Aug; 53(31):5162-73. PubMed ID: 25062800
[TBL] [Abstract][Full Text] [Related]
45. A novel murine system for validating the specific targeting of peptides to light chain associated (AL) amyloid.
Beierle SP; Foster JS; Richey T; Stuckey A; Macy S; Kennel SJ; Wall JS
Amyloid; 2017 Mar; 24(sup1):74-75. PubMed ID: 28434353
[No Abstract] [Full Text] [Related]
46. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
Bellotti V; Mangione P; Merlini G
J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
[TBL] [Abstract][Full Text] [Related]
47. Differences in Protein Concentration Dependence for Nucleation and Elongation in Light Chain Amyloid Formation.
Blancas-Mejía LM; Misra P; Ramirez-Alvarado M
Biochemistry; 2017 Feb; 56(5):757-766. PubMed ID: 28074646
[TBL] [Abstract][Full Text] [Related]
48. Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis.
Clos AL; Lasagna-Reeves CA; Castillo-Carranza DL; Sengupta U; Jackson GR; Kelly B; Beachkofsky TM; Kayed R
Br J Dermatol; 2011 Dec; 165(6):1349-54. PubMed ID: 21729025
[TBL] [Abstract][Full Text] [Related]
49. Al amyloidosis.
Desport E; Bridoux F; Sirac C; Delbes S; Bender S; Fernandez B; Quellard N; Lacombe C; Goujon JM; Lavergne D; Abraham J; Touchard G; Fermand JP; Jaccard A;
Orphanet J Rare Dis; 2012 Aug; 7():54. PubMed ID: 22909024
[TBL] [Abstract][Full Text] [Related]
50. The amyloid fibrils of the constant domain of immunoglobulin light chain.
Yamamoto K; Yagi H; Lee YH; Kardos J; Hagihara Y; Naiki H; Goto Y
FEBS Lett; 2010 Aug; 584(15):3348-53. PubMed ID: 20580354
[TBL] [Abstract][Full Text] [Related]
51. Immunogold quantitation of immunoglobulin light chains in renal amyloidosis and kappa light chain nephropathy.
Silver MM; Hearn SA; Walton JC; Lines LA; Walley VM
Am J Pathol; 1990 May; 136(5):997-1007. PubMed ID: 1693473
[TBL] [Abstract][Full Text] [Related]
52. Recruitment of Light Chains by Homologous and Heterologous Fibrils Shows Distinctive Kinetic and Conformational Specificity.
Blancas-Mejía LM; Ramirez-Alvarado M
Biochemistry; 2016 May; 55(21):2967-78. PubMed ID: 27158939
[TBL] [Abstract][Full Text] [Related]
53. Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.
Blancas-Mejía LM; Hammernik J; Marin-Argany M; Ramirez-Alvarado M
J Biol Chem; 2015 Feb; 290(8):4953-4965. PubMed ID: 25538238
[TBL] [Abstract][Full Text] [Related]
54. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis.
Diomede L; Rognoni P; Lavatelli F; Romeo M; del Favero E; Cantù L; Ghibaudi E; di Fonzo A; Corbelli A; Fiordaliso F; Palladini G; Valentini V; Perfetti V; Salmona M; Merlini G
Blood; 2014 Jun; 123(23):3543-52. PubMed ID: 24665135
[TBL] [Abstract][Full Text] [Related]
55. Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics.
Rognoni P; Mazzini G; Caminito S; Palladini G; Lavatelli F
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577839
[TBL] [Abstract][Full Text] [Related]
56. A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin λ6 Light Chain Promotes Pathologic Amyloid Formation.
Peterle D; Klimtchuk ES; Wales TE; Georgescauld F; Connors LH; Engen JR; Gursky O
J Mol Biol; 2021 Dec; 433(24):167310. PubMed ID: 34678302
[TBL] [Abstract][Full Text] [Related]
57. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.
Khurana R; Gillespie JR; Talapatra A; Minert LJ; Ionescu-Zanetti C; Millett I; Fink AL
Biochemistry; 2001 Mar; 40(12):3525-35. PubMed ID: 11297418
[TBL] [Abstract][Full Text] [Related]
58. Splenic plasma cells can serve as a source of amyloidogenic light chains.
Solomon A; Macy SD; Wooliver C; Weiss DT; Westermark P
Blood; 2009 Feb; 113(7):1501-3. PubMed ID: 19050307
[TBL] [Abstract][Full Text] [Related]
59. Interaction between glycosaminoglycans and immunoglobulin light chains.
Jiang X; Myatt E; Lykos P; Stevens FJ
Biochemistry; 1997 Oct; 36(43):13187-94. PubMed ID: 9341206
[TBL] [Abstract][Full Text] [Related]
60. Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis.
Karimi-Farsijani S; Pfeiffer PB; Banerjee S; Baur J; Kuhn L; Kupfer N; Hegenbart U; Schönland SO; Wiese S; Haupt C; Schmidt M; Fändrich M
Nat Commun; 2024 Jun; 15(1):5121. PubMed ID: 38879609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
